Home Blog Page 1359

Willog to Unveil Next-Gen ‘Control Tower 2.0’ at Manifest 2026, Accelerating Global Expansion with Series B-2 Funding

  • Showcasing ‘Control Tower 2.0’: Incorporating patented AIoT technology for hyper-precise visibility and intelligence across the entire logistics process.
  • Proven Technology: Secures third investment round (Series B-2) within just four years of establishment.
  • Confidence in Innovation: Offering immediate on-site PoC opportunities for attendees to experience logistics transformation.

SEOUL, South Korea, Feb. 3, 2026 /PRNewswire/ — Willog (https://willog.io/en), a leading provider of AIoT-based supply chain intelligence solutions, announced today that it will participate in Manifest 2026, the world’s largest logistics tech conference held in Las Vegas from February 9 to 11. At the event, Willog will unveil its next-generation supply chain management solution, ‘Control Tower 2.0,’ for the first time.

Manifest 2026, Accelerating Global Expansion with Series B-2 Funding
Manifest 2026, Accelerating Global Expansion with Series B-2 Funding

Alongside this product launch, Willog announced the successful closure of its Series B-2 funding round. This marks the company’s third successful investment round in just four years, following Series A in 2021 and Series B in 2023. This achievement serves as a significant validation of Willog’s sustained growth and differentiated technological capabilities in the competitive global market.

Introducing Control Tower 2.0: The Evolution of Visibility

The ‘Control Tower 2.0,’ debuting at Manifest 2026, is an integrated management solution that covers the entire supply chain—from warehouse storage to domestic and international transport. Its core strength lies in providing seamless, end-to-end visibility based on high-precision data collected via Willog’s proprietary, patented IoT sensor devices.

Going beyond simple location tracking, Control Tower 2.0 delivers true ‘Logistics Intelligence.’ The solution utilizes advanced algorithms to precisely analyze critical environmental variables collected by sensors, including temperature, humidity, shock, tilt, and light. By predicting potential issues in advance and analyzing historical data to prevent future risks, Willog provides enterprises with actionable results, supporting cost reduction and strategic optimization.

Experience-Centric Booth & Live Demos

Willog has designed its booth at Manifest 2026 not just as a display, but as an experience-centric space where visitors can tangibly feel the solution’s value. Attendees can get hands-on with the physical lineup of Willog’s diverse IoT sensor devices. Furthermore, the experience zone will feature vivid live demos showing exactly how Control Tower 2.0 visualizes real-world data and derives meaningful insights.

Exclusive On-Site Offer: Free PoC Program

A key highlight of Willog’s presence is the on-site Proof of Concept (PoC) program. Willog is offering a complimentary opportunity for qualified booth visitors to deploy its IoT devices and Control Tower solution directly into their actual logistics operations. This initiative allows potential clients to verify technological effectiveness in their specific environments and experience data-driven logistics innovation with zero financial burden.

This Series B-2 investment serves as market validation of Willog’s vision for the digital transformation of supply chains, said a spokesperson for Willog. The PoC opportunity we are offering at Manifest 2026 is an expression of Willog’s strong confidence in its technology. It will serve as a moment for global customers to truly experience logistics innovation through practical intelligence.

For more information on Willog’s participation in Manifest 2026 and to schedule a pre-meeting, please visit the official event page at https://event.willog.io/.

About Willog

Willog is a premier AIoT-based supply chain solution provider that goes beyond simple location tracking to ensure transparency and predictability across the entire logistics process. Utilizing proprietary, patented IoT devices, Willog accurately collects not only real-time location data but also critical environmental metrics affecting cargo integrity, including temperature, humidity, shock, tilt, and light exposure.

This collected data is analyzed using proprietary algorithms specialized for specific logistics domains, allowing the system to predict potential disruptions and proactively prevent risks based on historical patterns. This enables real-time comprehensive monitoring of all logistics assets, including moving cargo and goods stored within facilities. By forecasting and managing every stage of the supply chain, Willog empowers enterprises to optimize their logistics strategies while minimizing costs and risks.

Recognized for its technological prowess, Willog continues its rapid growth trajectory, having successfully secured Series B-2 funding recently, following Series A in 2021 and Series B in 2023. The company was also honored with a Presidential Citation at the ‘2025 Venture Business Promotion Merit’ awards in South Korea. Currently, Willog is accelerating its global expansion through its U.S. subsidiary.

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico’s generative AI engine.

CAMBRIDGE, Mass., Feb. 3, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group (“Menarini”) as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability.  

As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. (“Stemline”), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025.

“The program rapidly advanced into a Phase I clinical trial and successfully completed first patient dosing, fully demonstrating Menarini and Stemline’s exceptional agility and clinical expertise,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This milestone shows our shared commitment to delivering innovative therapies for cancer treatment. We are proud to further strengthen our partnership and encouraged to see AI-discovered drug candidates reaching such a critical stage, bringing us closer to providing novel treatment options for patients worldwide.”

“Getting the first patient dosed in our MEN2501 Phase 1 study is a meaningful milestone that underscores how quickly promising science can move forward through focused clinical execution,” said Elcin Barker Ergun, CEO of the Menarini Group. “We value our partnership with Insilico as we translate AI-enabled discovery into clinical programs, with the goal of bringing new, transformational treatment options to patients facing aggressive cancers.”

The collaboration between Insilico and Menarini has continued to expand since its inception. Prior to MEN2501, in January 2024, Insilico announced that it entered into an exclusive global license collaboration with Menarini for MEN2312, a novel KAT6 inhibitor for breast cancer and other oncology indications, with the combined value of the agreements exceeding USD 500 million. The MEN2312 program has progressed smoothly into clinical development, and Insilico has received early development milestone payments.

In addition to the collaboration pipelines, Insilico has extensive experience in AI-driven oncology, drug discovery and development. The company has established a robust oncology pipeline that targets multiple cancer indications, leveraging both moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program. 

About Insilico Medicine 

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

Metabolon Names Andrew Messick Chief Financial Officer

Seasoned life sciences finance leader brings deep expertise in operational excellence and M&A to support Metabolon’s next stage of growth

MORRISVILLE, N.C., Feb. 3, 2026 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces the appointment of Andrew (Drew) Messick as Chief Financial Officer.

“Drew brings more than 25 years of financial leadership experience, with a proven track record of driving growth through financial and operational excellence in the life sciences sector.  His expertise will be invaluable as Metabolon continues to scale and execute on its strategic objectives,” said Rohan Hastie, Ph.D., President and CEO of Metabolon. “Drew’s appointment further strengthens Metabolon’s executive leadership team as we expand our capabilities and market presence.”

Drew is an accomplished finance executive with over a decade of experience leading finance and operations for privately held life sciences companies. Over his career, he has served as Chief Financial Officer for multiple organizations, building high-performing teams, optimizing financial and operational processes, and successfully navigating mergers and acquisitions.

Drew is a graduate of the University of North Carolina at Chapel Hill, where he earned a Bachelor of Science in Business Administration and a Master of Accounting from UNC’s Kenan-Flagler Business School. He is both a Chartered Financial Analyst (CFA) and a Certified Public Accountant (CPA). Drew resides in Cary, North Carolina, with his wife and three children.

“Metabolon’s scientific leadership and differentiated multiomics capabilities position the company for long-term success,” said Andrew Messick, Chief Financial Officer. “I’m excited to join the team and look forward to supporting Metabolon’s continued growth through disciplined financial management and operational rigor.”

For more information about Metabolon’s services, please visit:

About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies.  With 25 years of experience, 15,000+ client projects, 4,000+ scientific publication references, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.  Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library.  Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system.  Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

Aixio Introduces New AI Models for Photoshop-like Editing with Sketches and Doodles

PALO ALTO, Calif., Feb. 3, 2026 /PRNewswire/ — With generative AI transforming the creative landscape, Aixio is introducing a revolutionary platform designed to streamline the editing of photos and videos through intuitive sketching. Officially launched in February 2026, Aixio offers AI-powered models and products that empower users to create and refine multimedia content effortlessly, all with simple sketches and doodles.

While many AI tools in the market generate content based on text prompts, they often fall short in enabling precise and high-quality edits that integrate smoothly into professional workflows. Aixio changes this by allowing users to sketch their ideas directly on the platform, which interprets and refines those designs with AI precision. Whether editing images or videos, Aixio makes it easier than ever for creators to express their ideas and refine them in real time.

Editing Made Simple: From Sketch to Final Product

Aixio’s core innovation is its seamless integration of sketches for photo and video editing, offering a natural and intuitive way to edit media.

  • Sketching for Photos and Videos: Users can quickly sketch their ideas or make adjustments to existing media, whether it’s a photo or video. Aixio’s AI understands and enhances hand-drawn sketches, transforming rough ideas into polished, professional content.
  • AI-Powered Refinements: Once a sketch is made, the AI steps in to refine the image or video, ensuring that the result meets the professional standards needed for any creative project. The platform’s AI models focus on delivering high-quality, realistic results that are ready for use in production.


Harnessing the Power of AI for Precise Edits

At the heart of Aixio is Aixio Image v1, a custom AI model that powers the photo editing experience. Trained on millions of high-quality data points, it’s optimized to handle everything from simple tweaks to complex adjustments, making it perfect for professional creative tasks.

Unlike other AI platforms, Aixio ensures pixel-perfect consistency across photos and videos. Even in areas that aren’t being actively edited, the platform’s AI maintains the integrity of the original content, eliminating distortions and inaccuracies.

Optimized for Professional Workflows

Designed for industries like film, graphic design, and manga, Aixio’s photo and video editing features cater specifically to the needs of professionals.

  • For Filmmakers: Aixio allows for efficient editing and adjustments, including scene continuity and frame-to-frame consistency, all through simple sketches and AI-powered enhancements.
  • For Graphic Designers: Designers can easily refine images or create complex visual compositions with just a few sketches, eliminating the need for time-consuming, manual editing.
  • For Manga Artists: The platform’s AI helps maintain visual consistency across illustrations, whether you’re working on a single page or a full series, giving artists more control over the creative process.


AI-Enhanced Workflows for Speed and Precision

Aixio is more than just a platform for creating beautiful visuals—it’s designed to integrate seamlessly into existing workflows, offering tools that increase both speed and accuracy. By focusing on sketch-based editing, Aixio reduces the complexity of traditional image and video editing processes, allowing creators to focus more on their craft and less on technical hurdles.

Future-Ready AI for Evolving Creative Needs

The Aixio team, consisting of AI and design experts, is committed to evolving the platform beyond its current capabilities. Aixio already boasts over 30,000 users, with 72% identifying as creative professionals, and the company has plans to expand into dynamic content creation and 3D editing in the future.

“We believe that creativity should be intuitive and natural,” said the Aixio team. “Our goal is to make the creative process faster, more precise, and more enjoyable, using the power of AI to bring your sketches and ideas to life.”

Fac Tec China 2026: Your Gateway to the Factories of Tomorrow – Driving Efficiency, Safety, and Sustainability

SHANGHAI, Feb. 3, 2026 /PRNewswire/ — Organized by RX, Fac Tec China will take place from June 2–4, 2026, at the Shanghai World Expo Exhibition & Convention Center. This premier trade event comes at a pivotal moment for the global electronics manufacturing industry, as companies face mounting pressure to improve efficiency, adopt sustainable practices, and upgrade to intelligent, flexible factory systems. Global demand for advanced manufacturing solutions in semiconductors, automotive electronics, PCB, and 3C electronics is projected to grow steadily over the next five years, making it crucial for industry professionals to stay ahead of technological trends and operational innovations.

Spanning over 25,000 m², Fac Tec China 2026 will host more than 200 exhibitors and feature 20+ industry-focused summits and activities, including the Future Facility Showcase, Business Strategy Summit, Technical Seminars, and tailored matchmaking sessions. Exhibitors will showcase solutions across critical segments such as green factory technologies, factory safety and disaster prevention & maintenance solutions, environment control solutions, consumables and new materials, and smart & flexible manufacturing solutions, with applications in 3C electronics, automotive electronics, wireless communication systems, new energy, semiconductors, and rail transit technologies.

Show floor highlights include the China Anti-Electrostatic Industry Show, EPA Demonstration Area, Japan Electronics and Automation Zone, Semiconductor Packaging and Testing Demo, Automotive Electronics Disassembly Zone, and the Green Recycling Experience, presenting the latest innovations and practical technological advances.

The event will also feature a rich lineup of high-level activities, including the “Next-Generation Factory” Summit, industry forums, technology think tanks, competitions, and business matchmaking sessions. Exclusive programs such as Country Days, tech salons, factory tours, and tailored overseas buyer sessions from regions including Vietnam, Malaysia, and Thailand provide added value and engagement opportunities.

Join Fac Tec China 2026 to stay ahead of industry trends, explore breakthrough manufacturing solutions, and strengthen your global network—ensuring your business remains competitive in a rapidly evolving electronics manufacturing landscape.

If interested in exhibiting at Fac Tec China 2026, please contact 
Ms. Julia Gu
Tel: +86 21-2231-7010
Email: Julia.gu@rxglobal.com 

If interested in visiting Fac Tec China 2026, please contact 
Mr. Walden Li 
Email:  walden.li@rxglobal.com , nepconacrosschina@reedexpo.com.cn  
Mobile/WhatsApp/WeChat:  +86 136-5125-1335

For more information, please visit  Fac Tec China – your gateway to factories of tomorrow.

Pre-Register: ali2.infosalons.com.cn/reg/FTC26/Web/FTC26/index.html#/login?lang=en-US&page=public&type=9XU8RK

NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer

NEW YORK, Feb. 3, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer

Ashley Mastronardi delivers the pre-market update on February 3rd

  • Stocks are mixed as investors track a heavy week of corporate earnings — including reports from NYSE‑listed Pfizer, Eaton, Uber, and Eli Lilly — while labor data is disrupted by the postponement of Friday’s January Jobs Report due to the partial government shutdown.
  • With government data delayed, market attention is shifting to private‑sector indicators and corporate outlooks to gauge the strength of the U.S. economy.
  • NYSE-listed AstraZeneca scored a winning debut on the NYSE during Monday’s session, climbing 0.7%. The firm began trading on the exchange, marking the largest company transfer by market capitalization in NYSE history.

Opening Bell
Oracle Corporation (NYSE: ORCL) rings the Opening Bell

Closing Bell
Tyler Technologies (NYSE: TYL) celebrates its 60th birthday

Click here to check out Industry’s time at the NYSE

 

Locksley Announces High-Grade Antimony Results from Batch Sampling Program at its Mojave Project

SAN BERNARDINO, Calif., Feb. 3, 2026 /PRNewswire/ — Locksley Resources Limited (ASX: LKY; OTCQX: LKYRF; OTCQX ADR: LKYLY) announced that a batch sampling program at the DAM antimony (Sb) deposit, part of the Mojave Project in California,  returned high grade antimony results.

The batch sampling program, which was designed to further evaluate the high-grade antimony mineralization at DAM following technical milestones achieved in late 2025, including a 325kg sample and the production of a 68.1% Sb premium concentrate, targeted specific mineralized vein material within the historical workings. Detailed information can be found here: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03052293-6A1310222&v=undefined.

“The results exceeded our expectations,” said Kerrie Matthews, Locksley Managing Director and CEO. She added, “There were three batches sampled. Batch 1 returned a weighted average of 25.7% while Batches 2 and 3 sampling focused on both high-grade and low-grade material to provide a representative range for metallurgical testwork, returning weighted averages of 21.3% Sb and 11.4% Sb, respectively. The total weighted average grade of all samples combined (287kg) was 18.7% Sb.”

Matthews noted that Locksley’s consistent return of double-digit percentages at more than 25% underscores the potential for the Desert Antimony Mine. “We aren’t just looking at byproduct antimony; we are looking at a rich, primary source of a metal that the U.S. Department of Defense and the energy sector desperately need.”

Locksley Resources (https://www.locksleyresources.com.au) is focused on critical minerals in the U.S. The company is actively advancing the Mojave Project in California, targeting rare earth elements (REEs) and antimony. Locksley is executing a mine-to-market strategy for antimony, aimed at reestablishing domestic supply chains for critical materials, underpinned by strategic downstream technology partnerships with leading U.S. research institutions and industry partners. This targeted approach, combined with resource development with innovative processing and separation technologies, positions Locksley to play a role in advancing U.S. critical materials independence.

Contact: Beverly Jedynak, beverly.jedynak@viriathus.com, 312-943-1123; 773-350-5793 (cell)

Astreya Acquires Reliant Information Services to Expand Regulated Industry IT Capabilities

Acquisition strengthens compliance-ready delivery, expands enterprise footprint, and deepens support for mission-critical operations.

SAN JOSE, Calif., Feb. 3, 2026 /PRNewswire/ — Astreya, a leading AI-first global IT managed services and solutions provider, today announced it has entered into a definitive agreement to acquire Reliant Information Services, LLC from the Reliant Group. The transaction marks Astreya’s first business acquisition and represents a significant milestone in the company’s long-term growth strategy centered around providing best-in-class managed IT services for enterprise clients at scale, delivering excellent ROI.

For more than a decade, Reliant Information Services (RIS) has served as a trusted IT partner to Fortune 500 enterprises, delivering scalable managed IT services and providing managed technical expertise for mission-critical operations. The company brings deep experience supporting complex, high-availability IT environments across key markets in the western United States, including enterprise customers with stringent operational, security, and compliance requirements.

The acquisition expands Astreya’s presence in the airline industry and strengthens its position in providing managed IT services to client stakeholders where operational resilience, regulatory compliance, and service reliability are essential. Together, the combined organization will offer customers broader geographic coverage, including in the Pacific Northwest and Southwest United States, deeper domain expertise, and expanded service delivery capabilities to support increasingly complex technology environments.

“This acquisition represents an important step forward for Astreya,” said Romil Bahl, CEO of Astreya. “As our first business acquisition, it reflects our focus on thoughtful, strategic growth. Reliant brings expertise in regulated, mission-critical environments, along with a customer-first culture that closely aligns with ours. Importantly, they fit right into our 3×3 structure of practices and AI-first managed services offerings. Their long-standing enterprise relationship with a major airline operator, and their presence in the Pacific Northwest, further strengthen our ability to support our customers. Put this together with Astreya’s presence around the world, and our combined company is in a position to serve airline customers globally.”

As part of the transaction, the Reliant IS leadership team, led by Jesse Perbix, President of Reliant Information Services, will join Astreya. Perbix will serve as General Manager of RIS, ensuring continuity for customers, partners, and employees.

“Astreya stood out as the right strategic and cultural fit for the next phase of our growth,” said Scott Nguyen, CEO of Reliant Group. “After building the company from the ground up to more than 100 employees, it was critical to find a partner that values our people, our customers, and our approach to service delivery. This combination positions the business well for continued growth and long-term success, and I am excited to serve as an advisor to Reliant IS going forward as they scale new peaks as part of Astreya.”

Looking ahead, Astreya will continue to pursue strategic investments that strengthen industry expertise, expand its global footprint, and accelerate innovation while remaining focused on delivering measurable value, operational resilience, and trusted partnership for its customers.

About Astreya
Astreya is a global IT Managed Services provider that powers enterprises by designing, deploying, and managing complex technology environments. We deliver end-to-end solutions across hybrid cloud, data centers, network infrastructure, and the digital workplace. Intelligent automation and AI run through everything we build to drive efficiency, accelerate service delivery, and clear barriers to growth for our customers.

Learn more at www.astreya.com and follow Astreya on LinkedIn.